Last week’s Akron Biotech blog hiatus was due to our team’s focus on the International Society for Cellular Therapy (ISCT) annual meeting in Philadelphia, which took place between September 8-13. Akron Biotech enjoyed a successful presence at the annual meeting.
As a driver for translation of cellular therapies to benefit patients worldwide, ISCT brings together clinicians, industry professionals, regulatory bodies, researchers, and technical teams under one roof to share knowledge and ideas. The program highlighted the close working relationship between the academic, industry, patient care, and regulatory communities. Plenary sessions included: advances in cord blood expansion by Cellerant (clinical data), “universal donor allogeneic option” by Dr. Coleen Delaney and a discussion on the initial impact of Nicord from Gamida Cell by Duke University. There were updates on CAR-targeted T cells as well as MSC biology and Tissue Engineering and Organ Recellularization. Other planned sessions covered topics of interest in the areas of technical practice, manufacturing, quality, commercialization, and delivery of patient care. All sessions were well attended; for those interested, many of the power point presentations will be posted on the ISCT web site in the next few weeks. Dr. Zylberberg, our CEO, was the co-chair of this successful meeting, where more than 375 participants enjoyed a very high-impact agenda. For more information, visit http://www.isct.org.
Looking forward to our next stop: ISCT Latin America Regional Meeting in Lima, Peru October 2013.
Even when we’re on the road, however, science at Akron Biotech does not stop. We have long been championing the importance of environments for culture of stem cells that address critical parameters, such as mechanics and vascularity of more intricate organs and tissues. In other words, we recognize and cannot stress enough the importance of culturing stem cells inside 3D microenvironments that more accurately mimic the behavior of in vivo tissue. Recent developments in 3D culture engineering have been the subject of a number of recent literature reviews (Deluzio et al., Pharmaceutical Bioprocessing 2013).
One technique that closely imitates the biomaterial structures of ECM tissue is electrospinning. Electrospinning produces nonwoven scaffolds made of nanofibers. Akron’s 3D scaffolds – Polyfibers – are electrospun polymeric nanofibers that provide a unique environment for cellular differentiation. Akron’s Polyfibers have enjoyed a slew of successful uses and applications – and we’d love to hear of yours. For those of you who are still on fence or simply want to learn more about 3D scaffolds, and electrospinning of polymer scaffolds in particular, we have included the video below, which gives a simple overview of electrospinning for the culture of stem cells, courtesy of Jason Burdick’s lab at the University of Pennsylvania. If you have not tried our scaffolds before, why not do it now? We are available to support you along the way, and we’d love to hear about your application.
JoVE: Electrospinning Fibrous Polymer Scaffolds for Tissue Engineering and Cell Culture (Ifkovits et al., 2009)